Kane Biotech Inc.
KNE.V
TSX
| 03/31/2025 | 12/31/2024 | 09/30/2024 | 06/30/2024 | 03/31/2024 | |
|---|---|---|---|---|---|
| Net Income | -9.75% | -74.16% | -106.62% | 748.18% | 10.97% |
| Total Depreciation and Amortization | -26.65% | 33.53% | -14.36% | -1.00% | -6.53% |
| Total Amortization of Deferred Charges | -- | -- | -- | -- | -- |
| Total Other Non-Cash Items | -50.79% | 197.40% | 101.27% | -4,902.10% | -59.07% |
| Change in Net Operating Assets | -165.80% | 277.49% | 89.96% | -839.70% | -30.62% |
| Cash from Operations | -156.42% | 23.98% | 75.11% | -117.15% | -25.73% |
| Capital Expenditure | -200.00% | 13.51% | 50.67% | -97.37% | 19.15% |
| Sale of Property, Plant, and Equipment | -- | -- | -- | -- | -- |
| Cash Acquisitions | -- | -- | -- | -- | -- |
| Divestitures | -- | -- | -- | -- | -- |
| Other Investing Activities | 17.18% | -948.00% | 99.33% | -142.02% | 48.18% |
| Cash from Investing | -238.05% | 464.52% | -100.09% | 642.40% | 48.71% |
| Total Debt Issued | -- | -- | -- | -- | -- |
| Total Debt Repaid | -0.26% | -0.26% | 97.50% | -3,086.69% | -26.54% |
| Issuance of Common Stock | 291.74% | 48.93% | -- | -- | -- |
| Repurchase of Common Stock | -- | -- | -- | -- | -- |
| Issuance of Preferred Stock | -- | -- | -- | -- | -- |
| Repurchase of Preferred Stock | -- | -- | -- | -- | -- |
| Total Dividends Paid | -- | -- | -- | -- | -- |
| Other Financing Activities | 3.73% | 2.90% | 99.03% | -580.63% | -150.76% |
| Cash from Financing | 517.54% | 143.77% | 101.07% | -1,759.33% | -267.98% |
| Foreign Exchange rate Adjustments | -- | -- | -- | -- | -- |
| Miscellaneous Cash Flow Adjustments | -- | -- | -- | -- | -- |
| Net Change in Cash | 170.81% | 61.15% | 32.70% | -269.88% | -170.24% |